Keywords: Transition Thera, Eli Lilly, Diabetes drug, TT-223, Fails to meet endpoints

Transition Thera/Eli Lilly’s abandon diabetes drug TT-223 after it fails to meet endpoints

Article | 20 September 2010

Print This

Canada’s Transition Therapeutics that a clinical study of gastrin analogue TT-223 in combination with an Eli Lilly (NYSE: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in